Koelbl H, Schieder K, Neunteufel W, Bieglmayer C
2nd Department of Obstetrics and Gynecology, University of Vienna, Austria.
Eur J Obstet Gynecol Reprod Biol. 1988 Apr;27(4):335-42. doi: 10.1016/0028-2243(88)90047-0.
Three hundred and ninety-five CA 125 serum values of 72 patients with ovarian cancer were correlated with the clinical status. With a threshold value of 35 U/ml we found true negative values in 85% and true positive values in 93%. No correlation between preoperative CA 125 values and tumor stage was noted at primary surgery. During follow-up, 17 women had marker values between 35 and 65 U/ml. Three out of 7 women in clinical remission showed a value greater than 65 U/ml at subsequent follow-up and developed recurrent disease. In 8 patients out of 20 re-laparotomies, tumors with a maximum diameter of greater than 2 cm were confirmed with a preoperative serum CA 125 concentration greater than 65 U/ml. Two out of 3 patients with a tumor diameter less than 2 cm at re-laparotomy revealed CA 125 serum concentrations less than 35 U/ml. A false positive CA 125 value was found in one patient without demonstrable active disease. The calculated doubling time of the CA 125 values ranged between 23 and 173 days; the median value was 67 +/- 47 days. After 6.2 +/- 1.3 doubling times death ensued.
对72例卵巢癌患者的395份CA 125血清值与临床状况进行了相关性分析。以35 U/ml为临界值，我们发现真阴性值占85%，真阳性值占93%。在初次手术时，未发现术前CA 125值与肿瘤分期之间存在相关性。在随访期间，17名女性的标志物值在35至65 U/ml之间。7名临床缓解的女性中有3名在随后的随访中显示值大于65 U/ml，并出现了复发疾病。在20例再次剖腹手术的患者中，有8例术前血清CA 125浓度大于65 U/ml，证实存在最大直径大于2 cm的肿瘤。再次剖腹手术时肿瘤直径小于2 cm的3例患者中有2例CA 125血清浓度小于35 U/ml。在1例无明显活动性疾病的患者中发现了假阳性CA 125值。计算得出的CA 125值的倍增时间在23至173天之间；中位数为67±47天。经过6.2±1.3个倍增时间后患者死亡。
